|Bid||1.9600 x 40000|
|Ask||1.9900 x 34100|
|Day's Range||1.8800 - 2.0100|
|52 Week Range||1.6000 - 10.3300|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.67|
In the early days of the coronavirus vaccine race, Inovio Pharmaceuticals (NASDAQ: INO) was one of the favorites. One major headwind slowed things down: The U.S. Food and Drug Administration (FDA) placed Inovio's coronavirus vaccine trial on a partial clinical hold in late 2020. Does all of this mean Inovio is in trouble?
Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals Inc will discontinue a late-stage study of its COVID-19 vaccine, the company said on Tuesday, and appointed its operating chief as the new chief executive, sending the company's shares down nearly 20% after the bell. The decision on the trial comes after emerging global data showed a lower incidence of severe COVID cases, which would lead to an increase in trial size and costs, the company said. The biotechnology company's new strategy also comes with a change at the helm, with Jacqueline Shea taking over as CEO, effective immediately.